Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Omkar PharmachemBOM:532167 52 Current Ratio is 5.96 as of Mar. 2026, which is 1556% above its 10-year median of 0.36. GuruFocus rates BOM:532167 with a GF Score™ of 52/100 and a GF Value™ of ₹23.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,091 Business Services companies, Omkar Pharmachem ranks better than 92.48% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Omkar Pharmachem's current ratio for the quarter that ended in Mar. 2026 was 5.96.
Omkar Pharmachem has a current ratio of 5.96. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Omkar Pharmachem's Current Ratio or its related term are showing as below:
BOM:532167'
s Current Ratio Range Over the Past 10 Years
Min: 0.03 Med: 0.36 Max: 5.96
Current: 5.96
During the past 13 years, Omkar Pharmachem's highest Current Ratio was 5.96. The lowest was 0.03. And the median was 0.36.
BOM:532167's Current Ratio is ranked better than 92.48% of 1091
companies
in the Business Services industry
Industry Median: 1.83
vs BOM:532167: 5.96
Omkar Pharmachem (BOM:532167) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Omkar Pharmachem Current Ratio Related Terms
Omkar Pharmachem Current Ratio Historical Data
* Premium members only.
The historical data trend for Omkar Pharmachem's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532167 vs CTAS, CPRT, GPN: Current Ratio Comparison
For the Specialty Business Services subindustry, Omkar Pharmachem's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omkar Pharmachem Current Ratio vs Business Services Industry
For the Business Services industry and Industrials sector, Omkar Pharmachem's Current Ratio distribution charts can be found below:
* The bar in red indicates where Omkar Pharmachem's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omkar Pharmachem (BOM:532167) has a Current Ratio of 5.96 as of Mar. 2026. This is 1556% above median its historical median of 0.36. Over the past decade, Omkar Pharmachem's Current Ratio has ranged from 0.03 to 5.96. According to the industry distribution chart, Omkar Pharmachem ranks #82 out of 1091 companies in the Business Services industry, placing it in the top 7.5%.
Is Omkar Pharmachem's Current Ratio too high?
Omkar Pharmachem's current Current Ratio of 5.96 is 1556% above median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 5.96. The Business Services industry median Current Ratio is 1.83. Omkar Pharmachem's value of 5.96 is 225.7% above this industry median. Based on the distribution chart, Omkar Pharmachem ranks #82 out of 1091 companies in the Business Services industry, which is in the top quartile — a strong position relative to peers. Overall, Omkar Pharmachem has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Omkar Pharmachem's Current Ratio compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Omkar Pharmachem ranks #82 out of 1091 companies for Current Ratio. This places Omkar Pharmachem in the top 8% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.83. Omkar Pharmachem's value of 5.96 is 225.7% above this benchmark. Historically, Omkar Pharmachem's own Current Ratio has ranged from 0.03 to 5.96 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 1.83, Omkar Pharmachem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Business Services company?
The median Current Ratio among Business Services companies is 1.83, based on 1,091 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omkar Pharmachem's current Current Ratio of 5.96 is 225.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Business Services industry, the median Current Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omkar Pharmachem's current Current Ratio is 5.96, which is 1556% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omkar Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Omkar Pharmachem (BOM:532167) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹23.90, compared to a current price of ₹16.30 — trading 31.8% below its estimated fair value. The current Current Ratio is 5.96, which is 1556% above median its 10-year median of 0.36 and 225.7% above the Business Services industry median of 1.83. Omkar Pharmachem's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Omkar Pharmachem (BOM:532167), the current Current Ratio is 5.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omkar Pharmachem (BOM:532167) Overvalued in 2026?
Based on GuruFocus' analysis, Omkar Pharmachem stock appears to be undervalued.
The current stock price of ₹16.30 is trading 31.8% below its estimated GF Value™ of ₹23.90.
GuruFocus considers Omkar Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:532167:
Current Ratio: 5.96 (1556% above median its 10-year median of 0.36)
GF Value™: ₹23.90 vs. price of ₹16.30 (31.8% below fair value)
Industry Position: 225.7% above the Business Services median (#82 of 1091)
No single metric tells the full story. See the BOM:532167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532167 has been successfully added to your 
